At Johnson & Johnson Consumer Health, we are committed to helping individuals and communities around the world manage the unprecedented impacts of COVID-19. Our teams are actively working to maintain production of high-demand consumer health products, including LISTERINE® brand products.
Our mouthwash is in high demand as consumers focus on personal hygiene. We are prioritizing the continued production of high-demand products to maintain supply, all while ensuring a high level of quality and safety.
LISTERINE® Antiseptic is an antimicrobial mouthwash that is clinically proven to kill germs that cause plaque, bad breath and the early gum disease, gingivitis. LISTERINE® Antiseptic is not intended to prevent or treat COVID-19 and should be used only as directed on the product label.
Although there are recent lab-based reports (in vitro studies) of some LISTERINE® Mouthwashes having activity against enveloped viruses, including coronavirus, the available data is insufficient, and no evidence-based clinical conclusions can be drawn with regards to the anti-viral efficacy of LISTERINE® Antiseptic mouthwash at this time.
Our understanding of the course of COVID-19 disease transmission continues to evolve. More research is needed to understand whether the use of mouthwashes can impact viral transmission, exposure, viral entry, viral load and ultimately affect meaningful clinical outcomes.
As a company firmly rooted in science, we are actively participating in scientific dialogue with study investigators around the globe.
For more information visit Johnson & Johnson’s COVID-19 Response.
USE AS DIRECTED
There have been consumer questions around the effectiveness of LISTERINE® against COVID-19. The health and safety of our consumers is paramount. Here are some frequently asked questions with answers from the makers of LISTERINE®.